Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 24;60(6):837-852.e3.
doi: 10.1016/j.devcel.2024.12.003. Epub 2024 Dec 24.

Tuft cells transdifferentiate to neural-like progenitor cells in the progression of pancreatic cancer

Affiliations

Tuft cells transdifferentiate to neural-like progenitor cells in the progression of pancreatic cancer

Daniel J Salas-Escabillas et al. Dev Cell. .

Abstract

Pancreatic ductal adenocarcinoma (PDA) is partly initiated through the transdifferentiation of acinar cells to metaplasia, which progresses to neoplasia and cancer. Tuft cells (TCs) are chemosensory cells not found in the normal pancreas but arise in cancer precursor lesions and diminish during progression to carcinoma. These metaplastic TCs (mTCs) suppress tumor progression through communication with the tumor microenvironment, but their fate during progression is unknown. To determine the fate of mTCs during PDA progression, we created a dual recombinase lineage trace model, wherein a pancreas-specific FlpO was used to induce tumorigenesis, while a tuft-cell specific Pou2f3CreERT/+ driver was used to induce expression of a tdTomato reporter. We found that mTCs in carcinoma transdifferentiate into neural-like progenitor cells (NRPs), a cell type associated with poor survival in patients. Using conditional knockout and overexpression systems, we found that Myc activity in mTCs is necessary and sufficient to induce this tuft-to-neuroendocrine transition (TNT).

Keywords: cellular plasticity; lineage trace; metaplasia; transdifferentiation.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests R.C.S. serves as a Scientific Advisory Board member and consultant for Rappta Therapeutics and has received sponsored research from Cardiff Oncology and AstraZeneca.

Update of

References

    1. Society, A.C. (2024). Cancer Facts & Figures 2024. American Cancer Society.
    1. Waters AM, and Der CJ (2018). KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. Cold Spring Harbor Perspectives in Medicine 8, a031435. 10.1101/cshperspect.a031435. - DOI - PMC - PubMed
    1. Chu LC, Goggins MG, and Fishman EK (2017). Diagnosis and Detection of Pancreatic Cancer. The Cancer Journal 23, 333–342. 10.1097/ppo.0000000000000290. - DOI - PubMed
    1. Pihlak R, Weaver J, Valle J, and McNamara M (2018). Advances in Molecular Profiling and Categorisation of Pancreatic Adenocarcinoma and the Implications for Therapy. Cancers 10, 17. 10.3390/cancers10010017. - DOI - PMC - PubMed
    1. Sahin IH, Iacobuzio-Donahue CA, and O’Reilly EM (2016). Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy. Expert Opinion on Therapeutic Targets 20, 341–359. 10.1517/14728222.2016.1094057. - DOI - PMC - PubMed

Publication types

LinkOut - more resources